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Pharmacotherapeutic algorithms developed to treat heart failure in adults with acquired heart disease have often provided the template for treatment of ventricular dysfunction or heart failure symptoms in patients with underlying congenital heart disease. Superficially at least, this is not completely irrational, as 'congenital' patients often demonstrate similar levels of functional incapacity and a neurohomonal profile similar to that seen in 'acquired heart failure' 1 . Scratch beneath the surface however, and the situation is much less clear. Systolic failure as the primary manifestation and driver of disease progression is rather rare, fundamentally the circulation in these patients is often quite different, and the rate of functional decline and adverse events tends to be substantially lower than that observed in the major studies of beta blockade and modifiers of the rennin-angiotensin system in acquired heart failure. Consequently there is an everincreasing catalog of, albeit small, randomized controlled trials that have failed to show a significant clinical benefit of these therapies in congenital heart disease [2] [3] [4] [5] [6] . The study by van der Bom and colleagues, examining the role of valsartan in patients with a systemic right ventricle (RV) and published in this issue of Circulation 7 can now be added to that list.
In congenital heart disease with a biventricular physiology, there are two main situations where the circulation depends on the RV's ability to drive blood through the systemic vascular bed. These are transposition of the great arteries (TGA) after an atrial-level surgical correction and congenitally corrected transposition of the great arteries (ccTGA). In both settings the RV is positioned beneath the aortic valve and is at high risk for long-term failure, the incidence of which increase with age. In each subgroup systemic RV dysfunction usually precedes the onset of clinical heart failure and once symptoms do occur, they are a strong predictor of mortality 8 .
By their mid-40s, over half of patients with ccTGA exhibit moderate-to-severe RV dysfunction and a similar proportion have developed clinical heart failure, outcomes that are strongly of the rennin-angiotensin system in acquired heart failure. Consequently there is s an an an eve ve er-rncreasing catalog of, albeit small, randomized controlled trials that have failed to show a i ign gn nif if ific ic ican an nt t t c cl cli i inic c cal al al b benefit of these therapies in c c con on o g genital heart di di ise s as ase e e 2-6 -6
2-. The study by van der B Bom m m and collea eagu g gues es, e ex exam am amin in inin in ing g th th he e e ro role le of va va valsar rta an n in n n p p pat at tie ient nt n s s wi with th a a sy ys yste te emi mi m c c ri ri righ gh ght t v ve vent n ntri i ricl cl c e e e associated with the presence and severity of tricuspid valve regurgitation 9 . The incidence of systemic RV dysfunction is similar for patients who have undergone atrial redirection procedures for TGA 10 . However, in this cohort clinical heart failure is somewhat less common and RV dysfunction predicts the risk of sudden cardiac death, which is the primary driver of mortality 8, 11, 12 . While the full arsenal of conventional heart failure therapy (lifestyle modification, medication, electrical therapies, transplant and ventricular assist device) can and have been employed in patients with a systemic RV, a lack of data specific to this population makes it difficult to know which strategy to adopt and who to target. Out of a desire to do something that might (even theoretically) help, when these patients develop more than mild systemic RV dysfunction or symptomatic heart failure, physicians often initiate medical treatment proven to be effective against heart failure in structurally normal hearts, usually an ACEi or ARB. A scientific understanding of not only the pathophysiology of functional decline, but also of the potential for such therapies to modify it underpins the success of such strategies in acquired heart failure. Unfortunately, for patients with a systemic RV, there is circumstantial evidence to suggest that neither the pathophysiology, nor the mechanism of action of treatment will be conducive of therapeutic success. For example, after atrial redirection procedures it appears that, consequent on the 'conduit function' of the baffles, it is a failure of atrioventricular coupling, with an inability to increase stroke volume with exercise or dobutamine stress 13, 14 which limits stroke volume and cardiac output responses. While this is demonstrably not an issue for those with ccTGA (who have normal stroke volume responses to exercise and dobutamine stress 15 ) evidence for primary RV myocardial failure is similarly lacking. Indeed, in an analysis of longterm outcomes in patients with ccTGA, those devoid of significant tricuspid (systemic) valve insufficiency remained free heart failure for decades 16 . Not only does this suggest that early dysfunction or symptomatic heart failure, physicians often initiate medical treat tm m ment nt n p p pro ro rove ve ven n n to to be effective against heart failure in structurally normal hearts, usually an ACEi or ARB. A c cie ie ent nt ntif if ifi ic ic u u und nd nderst st tan an andi d ng of not only the pathoph hys ys y io ology of funct tio io i na al l de de decl c ine, but also of the f f pote e en ntial for su such ch ch t t the her ra rapi pi pies es es t t to o o mo modi di d fy fy f i it u und d der r rpins s s t th he su su ucc cces ess s of of f s suc uch h h st str ra rate te egi gi gies es i i in n n ac ac auir ir ired ed ed h he ea e r fa ail il ilur ur ure e. e. U Unf nf nfor o ortu tun n nat te tely ly y, , fo fo for r pa a ati t t en en nts ts ts w w wit ith h h a a a sy sy syst tem em emi ic ic R RV V V, t t the he here re i i is s c c circ rc rcum um umst tan anti ti tial al l e evi vi ide de denc c ce e to to t uggest that n n nei ei eith th t er er er t the he he p pat t tho ho hoph ph phys ys ysio io olo lo l gy gy gy, , no no nor r th th the e me me mech ch c an an anis is sm m m of of of a a act t tio io ion n n of of of t t tre re reat at tme me ment nt nt w w will be attention to valve function might be a better therapeutic target in the latter group, but on the basis of their pathophysiologic substrates, afterload reduction as a therapeutic target may be flawed for either group, at least in the short-term.
In this issue of Circulation, Van der Bom and colleagues present a study that furthers our understanding of heart failure management in adult congenital patients with a systemic RV. The investigators are to be congratulated for conducting a 3-year, prospective, multi-center, doubleblind, placebo controlled trial of the angiotensin II type 1 receptor antagonist valsartan in patients with a systemic RV. This is no small achievement since well-designed trails in patients with congenital heart disease are notoriously difficult to complete 17, 18 . Although essentially a negative study, van der Bom et al's work nonetheless provides an important message for clinical practice and also, once again, illustrates the complexities and challenges of studying patients with congenital heart disease.
Six centers in the Netherlands took part in the study and potential participants were identified from CONCOR, the Dutch national registry and DNA-bank of ACHD patients.
Eighty-eight patients with a systemic RV in the setting of ccTGA or TGA after atrial redirection procedure were recruited and randomized in a 1:1 distribution to receive either placebo or 160mg valsartan twice a day for three years. Participants who were taking an ACEi prior to enrollment desisted for four weeks before the study began. Investigations were performed at baseline and as close to three years after enrollment as possible. The primary endpoint was RV ejection fraction (RVEF), measured by cardiac magnetic resonance imaging or computer tomography as determined by clinical factors such as the presence of a pacemaker. Valsartan was well tolerated and there were no excess adverse events int he valsartan group. At a mean follow-up of 3.2 years, RVEF remained unchanged in both the placebo patients (37.6±6.5% vs. 36.7 ±6.1%, negative study, van der Bom et al's work nonetheless provides an important mess ss sag g ge fo fo for r r cl cl clin in inic ical practice and also, once again, illustrates the complexities and challenges of studying patients wi with th h c c co on onge ge gen ni nit t tal he he hear art disease.
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Eighty-eight t p p pat at atie ie ent nt nts s s wi wi with t a a a s s sys ys yste te temi mi mic c c RV RV RV i i in n n th th the e e se se s tt tt t in in ing of of of c c ccT cT cTGA GA GA o o or r r TG TG TGA A A af af a te e er r at at atri ri ial al al redirection n n f f f f p=0.23) and those taking valsartan (34.9 ±7.4% vs. 35.1±9.6%, p=0.79) and the difference in RVEF between the two groups was not statistically significant. No statistical differences were found between the placebo and valsartan groups regarding changes in the degree of tricuspid regurgitation, parameters of exercise capacity, quality of life scores or neurohormonal activation during the course of the study and the groups showed no differences in the occurrence of clinical endpoints. Positive findings of the study relate to indices ventricular remodeling, which suggest valsartan may have tempered progression of RV dilatation and hypertrophy. However, only absolute values for these measurements are reported and it is unclear whether these findings would persist were the data presented in the more usual format, indexed for body surface area. VO2 were lower at baseline in the valsartan patients however. The authors conclude that their data fails to support the routine use of losartan in asymptomatic patients with a systemic RV but that therapy might be more appropriate is specific subgroups, especially those with symptoms.
The current study is important because it is one of only three prospective trials testing the effect of pharmacological treatment in patients with a systemic RV 4-6 . Moreover, it includes the largest number of patients studied to date and the longest duration of follow-up. Of the previous studies, two considered the effects of RAAS blockade 5, 6 . In a crossover study design, Dore et al.
compared the effects of twice daily losartan 50mg and placebo in 29 adults with either ccTGA or Mustard baffle 5 . After 15 weeks of treatment there were no differences in measures of exercise
The investigators performed additional subgroup analyses and here the important nt t f fin in nd di ding ng ng w w was as a hat in symptomatic patients RVEF and VO 2 peak declined during follow up in the placebo group k 3 36. 6. .9 9 9 ±8 ±8 ±8 8 . VO2 were low ow wer er e a a at t t ba ba base se seline ne ne i i in n n th th the e e va va vals s sar ar a ta ta tan n n pa pa pati ti t en en ents ts ts h how ow wev ev ever er e . . Th Th The au au auth th thor or ors s s co co c nc nc nclu lu lude It is time to ask whether the strength of this evidence is sufficient to dismiss potential theoretical benefits of ACEi and ARBs (reduction of fibrosis, inhibition of hypertrophy, reduction of sudden death) in this population and to change current clinical practice. Herein lies the problem with research in small and heterogenous patient groups. With the initial intent of recruiting >128 patients 22 and using a multi-centre approach, van der Bom and colleagues only managed to enroll 88 study participants out of 323 potentially eligible candidates. Of these, only 62 both continued the study medication until completion and underwent final evaluation.
Compare this to VAl-HeFt, which included 5010 patients with left ventricular dysfunction and found that 160mg of valsartan twice daily produced a 13% lower risk of the combined clinical end-point 23 . The original power calculation for the present study suggested a minimum of 102 patients were required for 80% power to detect a difference in ejection fraction of 5.6% 22 . It is therefore quite possible that van der Bom et al's trial was simply underpowered to detect evidence simply does not support the routine use of ACEi or ARBs in patients wi wi ith th h a s sys ys yste te temi m mic c f RV.
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h h heo o ore r tical bene nef fi f ts s o of f f AC AC ACE Ei Ei a an nd nd A A AR RB RBs s ( (red duc uc ction n n o o of fi fi fib br bros osis s, , in inhi hibi biti ti io on o of f hy hy hype pert rt tro ro r ph ph phy y, y e edu du duct ct ctio io i n n of of of s sud udde de den n d de eat at th) h) in n n th th his is is p p pop opu ul ulat at atio io ion n n an an and d to o o ch ha hang ng nge e e cu cu curr rren en ent t t cl cl c in in nic c cal al p p pra ra act ctic ic ice e e. H H Her r rei ein n lies es e he problem wi wi w th th t r r res es esea ea arc rc r h in in in s sma ma mall ll l a a and nd d h h het et eter er erog og oge e eno no nous us us p pat at atie ie ient nt nt g g gro ro roup up u s. s. s W W Wit it ith h h th th the e in in init it itia ia al l in intent of clinically relevant effects of valsartan therapy. One suspects that this argument, and the desire to 'do good' may remain stimuli for clinicians to continue treating these patients with conventional heart failure medications. Indeed, almost 60% of over 500 Fontan patients studied by The Pediatric Heart Network were receiving ACEi 24 , despite the only randomized, placebo controlled, cross-over trial of their use showing reduced cardiac output response to exercise during active treatment 3 . Alternatively, congenital heart disease specialists might abandon their slavish pursuance of therapies developed for treatment of heart failure with a completely different morphologic and pathophysiologic substrate, and instead identify new and more directly relevant targets for intervention. At the very least, the time is ripe for funding agencies and researchers to re-aim their focus on development of novel therapeutic solutions.
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